PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT –NONEXCLUSIVE COVER PAGEPatent License Agreement • September 12th, 2003 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement,” consists of this Cover Page, an attached agreement, a Signature Page, Appendix A (Patent or Patent Application), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Modifications) and Appendix E (Benchmarks). This Cover Page serves to identify the Parties to this Agreement as follows:
Amendment AgreementLicense Agreement • September 12th, 2003 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances
AMENDMENT TO LICENSE AGREEMENTLicense Agreement • September 12th, 2003 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances
This amendment is entered into between the President and Fellows of Harvard College (hereinafter HARVARD) having offices at the Office for Technology and Trademark Licensing, 124 Mt. Auburn Street, Suite 440, Cambridge, Massachusetts, 02138 and Virus Research Institute (hereinafter LICENSEE), a corporation, having offices at 61 Moulton Street, Cambridge, MA 02139.
LICENSE AGREEMENTLicense Agreement • September 12th, 2003 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • New York
THIS AGREEMENT, effective this 31st day of January, 2003, (“the Effective Date”) is entered into by AVANT IMMUNOTHERAPEUTICS, INC., (“AVANT” or “LICENSEE” herein) a Delaware corporation having its principal place of business at 119 Fourth Avenue, Needham, MA 02494, and ELAN DRUG DELIVERY LIMITED (“ELAN” or “LICENSOR” herein) an English corporation having its registered office at 1 Mere Way, Ruddington, Nottingham NG11 6JS, England.
AMENDMENT TO LICENSE AGREEMENTLicense Agreement • September 12th, 2003 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances
This amendment is entered into affective as of August 2, 2000 between the President and Fellows of Harvard College (hereinafter HARVARD) having offices at 25 Shattuck Street, Suite 414, Boston, MA 02115 and AVANT Immunotherapeutics, Inc. (hereinafter LICENSEE) having offices at 119 Fourth Avenue, Needham, Massachusetts 02494.
LICENSE AND CLINICAL TRIALS AGREEMENTLicense Agreement • September 12th, 2003 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • Ohio
Agreement (“AGREEMENT”), effective as of February 27, 1995 (“Effective Date”) between VIRUS RESEARCH INSTITUTE, INC., a Delaware corporation, with its principal place of business at 61 Moulton Street, Cambridge, Massachusetts 02138 (hereinafter referred to as “VRI”) and the JAMES N. GAMBLE INSTITUTE OF MEDICAL RESEARCH, an Ohio non-profit corporation, with its principal place of business at 2141 Auburn Avenue, Cincinnati, Ohio 45219 (hereinafter referred to as “GAMBLE”).
LICENSE AGREEMENTLicense Agreement • September 12th, 2003 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • Maryland
This Agreement, effective as of November 25, 1988 (“EFFECTIVE DATE”) is between The Johns Hopkins University, (JHU), a not-for-profit corporation of the State of Maryland, having a principal place of business at 720 Rutland Avenue, Baltimore, Maryland 21205 and Brigham and Women’s Hospital (BWH), a corporation of the State of Massachusetts, having a principal place of business at 75 Francis Street, Boston Massachusetts 02115 (JHU and BWH hereinafter referred to as “Licensor”) and T Cell Sciences, Inc. a Delaware Corporation, having a principal place of business at 840 Memorial Drive, Cambridge, MA 02139 (hereinafter the “Company”).
